9/20/2022 7:03:09 AM
Alnylam Receives Approval In Europe For AMVUTTRA For HATTR Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy
9/15/2022 7:05:35 AM
Alnylam And Regeneron Report Promising Data From Phase 1 Study Of ALN-HSD In NASH Patients And Healthy Volunteers
9/13/2022 6:13:50 AM
Alnylam Pharma Prices Offering Of $900 Mln Of 1.00% Convertible Senior Notes Due 2027
9/12/2022 6:49:16 AM
Alnylam Pharma Begins Private Offering Of $900 Mln Of Convertible Senior Notes Due 2027
9/8/2022 2:34:03 AM
Alnylam Presents Positive Results From Phase 3 Study Of Patisiran In ATTR Amyloidosis With Cardiomyopathy
8/29/2022 8:08:39 AM
Alnylam Pharma Reports Positive Results From Phase 2 Study Of Cemdisiran For Treatment Of IgA Nephropathy
8/24/2022 4:02:25 PM
Alnylam Appoints Elliott Sigal To Board Of Directors
8/3/2022 7:04:34 AM
Alnylam Reports Positive Topline Results From APOLLO-B Study Of Patisiran In ATTR Amyloidosis With Cardiomyopathy
7/28/2022 8:05:02 AM
Alnylam Pharma Q2 Loss Per Share $2.29; Non-GAAP Loss Per Share $2.03